Georgia Tomaras
Chief, Division of Surgical Sciences
A. Geller Distinguished Professor for Research in Immunology
Professor in Surgery
Professor in Integrative Immunobiology
Professor in Molecular Genetics and Microbiology
Affiliate, Duke Global Health Institute
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Jamieson PJ, Shen X, Abu-Shmais AA, Wasdin PT, Janowska K, Edwards RJ, et al. Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. J Virol. 2025 Dec 23;99(12):e0125625.Jons CK, Kasse CM, Mayer BT, Hyrien O, Sen S, Meany EL, et al. Hydrogel formulations for sustained-release of broadly neutralizing antibodies. J Control Release. 2025 Dec 10;388(Pt 2):114349.Moodie Z, Li SS, Giorgi EE, Williams LD, Dintwe O, Carpp LN, et al. A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. Emerg Microbes Infect. 2025 Dec;14(1):2485317.Conley HE, Oh SY, Garrett N, Kublin J, Monaco CL, Watts S, et al. IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial. J Acquir Immune Defic Syndr. 2025 Dec 1;100(4):371–5.
See more publications at Scholars@Duke